Drug intelligence / Profile preview

DACE

Development stage: Preclinical
Modality: Small Molecules
Administration: Intraperitoneal

Overview

DACE is a novel semisynthetic derivative of cucurbitacin B, developed as a potent inhibitor of non-small-cell lung cancer (NSCLC) cell proliferation. Its mechanism of action involves arresting the cell cycle of lung epithelial cells at the G2/M phase and inducing cell apoptosis. This is achieved by interfering with the activation of Epidermal growth factor receptor (EGFR) and its downstream signaling pathways, including AKT, ERK, and STAT3. In preclinical studies, intraperitoneal administration of DACE significantly suppressed the growth of mouse NSCLC.

Targets

EGFR (Epidermal growth factor receptor)

Beyond the preview

Go deeper on DACE.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DACE.

Explore the full profile